BioWorld

July 12, 2002

Serono Enlists Marketing Muscle' Of Pfizer In $200M Rebif Alliance

Serono SA is teaming up with Pfizer Inc. to co-promote the multiple sclerosis drug Rebif in the United States, which will position Rebif directly against Biogen Inc.'s powerhouse drug Avonex. (BioWorld Today) Read More

MedImmune Working Feverishly' On Resolving FluMist Concerns

Human Equivalent Of Nematode Dog-1 Implicates Mutated Protein In BRCA1 Breast Cancer Tumors

BioCryst Trims Staff, Changes Focus To Earlier-Stage Programs

Other News To Note

Bioethics Council Votes 10-7 For Therapeutic Cloning Moratorium

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

BioWorld Science

Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...

Investors bet on transformative BCI tech for neuro disorders

BioWorld

An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....